Rationale: The population of patients with pulmonary arterial hypertension (PAH) has evolved over time from predominantly young White women to an older, more racially diverse and obese population. Whether these changes are reflected in clinical trials is not known. Objectives: To determine secular and regional trends among PAH trial participants. Methods: We performed a pooled cohort analysis using harmonized data from phase III clinical trials of PAH therapies submitted to the U.S. Food and Drug Administration. We used mixed-effects linear and logistic regression to assess regional differences in participant age, sex, body habitus, and hemodynamics over time. Results: A total of 6,599 participants were enrolled in 18 trials between 1998 and 2013; 78% were female. The mean age of participants in North America, Europe, and Latin America at the time of study start increased by 2.09 (95% confidence interval [CI], 0.67-3.51), 1.62 (95% CI, 0.24-3.00), and 4.75 (95% CI, 2.29-7.21) years per 5 years, respectively (P = 0.01). Body mass index at the time of study start increased by 0.72 kg/m2 per 5 years (95% CI, 0.44-0.99; P < 0.001) across all regions. Eighty-five percent of participants in early studies were non-Hispanic White, but this decreased over time to 70%. Ninety-seven percent of Asians and 74% of Hispanics in the sample were recruited from Asia and Latin America. Conclusions: Patients enrolled in more recent PAH therapy trials are older and more obese, mirroring the changing epidemiology of observational cohorts. However, these trends varied by geographic region. PAH cohorts remain predominantly female, presenting challenges for generalizability to male patients. Although the proportion of non-White participants increased over time, this was primarily through recruitment in Asia and Latin America.
Rationale: The population of patients with pulmonary arterial hypertension (PAH) has evolved over time from predominantly young White women to an older, more racially diverse and obese population. Whether these changes are reflected in clinical trials is not known. Objectives: To determine secular and regional trends among PAH trial participants. Methods: We performed a pooled cohort analysis using harmonized data from phase III clinical trials of PAH therapies submitted to the U.S. Food and Drug Administration. We used mixed-effects linear and logistic regression to assess regional differences in participant age, sex, body habitus, and hemodynamics over time. Results: A total of 6,599 participants were enrolled in 18 trials between 1998 and 2013; 78% were female. The mean age of participants in North America, Europe, and Latin America at the time of study start increased by 2.09 (95% confidence interval [CI], 0.67-3.51), 1.62 (95% CI, 0.24-3.00), and 4.75 (95% CI, 2.29-7.21) years per 5 years, respectively (P = 0.01). Body mass index at the time of study start increased by 0.72 kg/m2 per 5 years (95% CI, 0.44-0.99; P < 0.001) across all regions. Eighty-five percent of participants in early studies were non-Hispanic White, but this decreased over time to 70%. Ninety-seven percent of Asians and 74% of Hispanics in the sample were recruited from Asia and Latin America. Conclusions: Patients enrolled in more recent PAH therapy trials are older and more obese, mirroring the changing epidemiology of observational cohorts. However, these trends varied by geographic region. PAH cohorts remain predominantly female, presenting challenges for generalizability to male patients. Although the proportion of non-White participants increased over time, this was primarily through recruitment in Asia and Latin America.
Authors: Corey E Ventetuolo; Grayson L Baird; R Graham Barr; David A Bluemke; Jason S Fritz; Nicholas S Hill; James R Klinger; Joao A C Lima; Pamela Ouyang; Harold I Palevsky; Amy J Palmisciano; Ipsita Krishnan; Diane Pinder; Ioana R Preston; Kari E Roberts; Steven M Kawut Journal: Am J Respir Crit Care Med Date: 2016-05-15 Impact factor: 21.405
Authors: Nazzareno Galiè; Joan A Barberà; Adaani E Frost; Hossein-Ardeschir Ghofrani; Marius M Hoeper; Vallerie V McLaughlin; Andrew J Peacock; Gérald Simonneau; Jean-Luc Vachiery; Ekkehard Grünig; Ronald J Oudiz; Anton Vonk-Noordegraaf; R James White; Christiana Blair; Hunter Gillies; Karen L Miller; Julia H N Harris; Jonathan Langley; Lewis J Rubin Journal: N Engl J Med Date: 2015-08-27 Impact factor: 91.245
Authors: S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner Journal: Ann Intern Med Date: 1987-08 Impact factor: 25.391
Authors: Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza Journal: Eur Respir J Date: 2019-01-24 Impact factor: 16.671
Authors: Olivier Sitbon; Mardi Gomberg-Maitland; John Granton; Michael I Lewis; Stephen C Mathai; Maurizio Rainisio; Norman L Stockbridge; Martin R Wilkins; Roham T Zamanian; Lewis J Rubin Journal: Eur Respir J Date: 2019-01-24 Impact factor: 16.671
Authors: Jessica B Badlam; David B Badesch; Eric D Austin; Raymond L Benza; Wendy K Chung; Harrison W Farber; Kathy Feldkircher; Adaani E Frost; Abby D Poms; Katie A Lutz; Michael W Pauciulo; Chang Yu; William C Nichols; C Gregory Elliott Journal: Chest Date: 2020-08-26 Impact factor: 9.410
Authors: Jeff Min; Rui Feng; David Badesch; Erika Berman-Rosenzweig; Charles Burger; Murali Chakinala; Teresa De Marco; Jeremy Feldman; Anna Hemnes; Evelyn M Horn; Matthew R Lammi; Stephen Mathai; John W McConnell; Kenneth Presberg; Jeffrey Robinson; Jeffrey Sager; Oksana A Shlobin; Marc Simon; Thenappan Thenappan; Corey Ventetuolo; Nadine Al-Naamani Journal: Ann Am Thorac Soc Date: 2020-10-21
Authors: Breanne E McCarthy; Robyn L McClelland; Dina H Appleby; Jude S Moutchia; Jasleen K Minhas; Jeff Min; Jeremy A Mazurek; K Akaya Smith; Jason S Fritz; Steven C Pugliese; Ryan J Urbanowicz; John H Holmes; Harold I Palevsky; Steven M Kawut; Nadine Al-Naamani Journal: Chest Date: 2022-03-03 Impact factor: 10.262